New Discovery: LRRK2 Therapies Could Benefit Wider Population | FoxFlash July 2018

Wider Population May Benefit from LRRK2 Therapies in Development New findings from a Foundation-funded study suggest that the LRRK2 protein may have a role in Parkinson's disease among people who don't carry the LRRK2mutation. This means that LRRK2-targeted treatments currently in development also could be useful for people without the mutation. Discover More > Urinary Problems in Parkinson's Disease Hear expert discussion and ask your questions in our Third Thursdays Webinar series.  August 16, 2018 at 12 p.m. ET Proposal Could Limit Regulation on Chemicals Linked to Parkinson's MJFF joined nearly 70 health, academic and scientific groups to call on the Environmental Protection Agency to strike down the proposed rule. Learn More > Our 2017 Annual Report: Roadmaps for Progress With $100 million in research programs funded, 2017 was a year marked by promise and progress. Explore our roadmaps for increasing PD understanding and speeding cures. Download Now > Looking for a Family-Friendly Activity this August? We have options! Parkour like a Ninja Warrior in Los Angeles, enjoy a Fox Trot in New York City, cycle through the vineyards of Santa Rosa, and more... Find Fundraisers > FDA Approves Treatment for Drooling in Parkinson's Xeomin (incobotulinumtoxinA) is the first and only botulinum approved for drooling. It works to decrease saliva production temporarily. Read More > Parkinson's Research Needs You Speed Parkinson's research from home. Participate in Fox Insight from your computer, tablet or cell phone. Join Now >